[Form 4] Anika Therapeutics Inc Insider Trading Activity

Rhea-AI Filing Summary

On 24 June 2025, Anika Therapeutics (ANIK) filed a Form 4 reporting that director Susan L. N. Vogt was granted 14,164 restricted stock units (RSUs) on 20 June 2025. Transaction code "A" confirms the award was a non-cash grant priced at $0.

Each RSU entitles the holder to one common share and will vest in full on the earlier of the 2026 annual shareholder meeting or 20 June 2026. Following the grant, Vogt's beneficial ownership increased to 50,213 common shares, a notable rise from her prior level.

No derivative securities, sales, or additional acquisitions are disclosed. The filing represents routine director compensation and is unlikely to materially affect Anika Therapeutics' financial condition or share-count, but it strengthens insider alignment with shareholder interests.

Insights

Corporate Governance Analyst

TL;DR: Routine RSU grant; increases director alignment, minimal financial impact.

The Form 4 reveals a standard equity compensation award—not an open-market purchase. Director Susan L. N. Vogt received 14,164 RSUs on 20 June 2025 at a grant price of $0, raising her beneficial stake to 50,213 common shares. The units vest by mid-2026, and no derivative instruments or stock sales were reported. As this is customary director remuneration, it should not influence valuation or liquidity, though it modestly strengthens insider ownership alignment. Overall market impact: neutral.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

VOGT SUSAN L N

(Last) (First) (Middle)

32 WIGGINS AVENUE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Anika Therapeutics, Inc. [ ANIK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/20/2025		A		14,164(1)	A	$0	50,213	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2026 annual meeting of the Company's stockholders or June 20, 2026.

	/s/ Susan Vogt	06/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many shares did Anika Therapeutics (ANIK) director Susan Vogt acquire?

She was granted 14,164 restricted stock units, each convertible into one common share.

What type of transaction is reported in the June 20, 2025 Form 4 for ANIK?

The filing lists an "A" transaction code, indicating a grant or award of securities, not an open-market purchase.

When do the newly granted RSUs to Susan Vogt vest?

The RSUs vest in full on the earlier of the 2026 annual shareholder meeting or June 20, 2026.

What is Susan Vogt’s total beneficial ownership in ANIK after this grant?

Following the award, she beneficially owns 50,213 shares of common stock.

Does the filing indicate any purchase price for the granted shares?

No; the RSUs were granted at $0 per share as part of director compensation.